GraniteShares Autocallable SMCI ETF (SCA)
NYSE NYSE Primary 
BVC 
Svenska Cellulosa Aktiebolaget SCA (publ) (SCABY) Q2 2026 Earnings Call Transcript
Svenska Cellulosa Aktiebolaget SCA (publ) (SCABY) Q2 2026 Earnings Call Transcript
Biohaven's Revenue Path: SCA And Obesity Therapies
Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials.
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the phase 3 study using troriluzole for patients with spinocerebellar ataxia, an NDA submission is planned for Q4 of 2024. Troriluzole is also being explored for patients with obsessive compulsive disorder in two phase 3 studies; Data from these studies are expected before the end of 2024 and the 1st half of 2025.
